Organization Overview
Alternative names
asparaginase (elspar) (2 trials)
cladribine (leustatin) (2 trials)
cyclophosphamide (cytoxan) (13 trials)
cytarabine (cytosar-u) (8 trials)
etoposide (vepesid) (8 trials)
fludarabine (fludara) (3 trials)
idarubicin (idamycin) (2 trials)
allogeneic stem cells (1 trial)
autologous mononuclear stem cell (1 trial)
blinatumomab (blincyto) (1 trial)
bortezomib (velcade) (1 trial)
dacarbazine (dtic-dome) (3 trials)
defibrotide (defitelio) (1 trial)
docetaxel (taxotere) (2 trials)
bleomycin (blenoxane) (1 trial)
carboplatin (paraplatin) (1 trial)
donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta (1 trial)
Adenocarcinoma (Phase 3)
Adenoma (Phase 2)
Adenoma, Villous (Phase 2)
Aggression (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Cholangiocarcinoma (Phase 3)
Gallbladder Neoplasms (Phase 3)
Glioblastoma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Hepatic Veno-Occlusive Disease (Phase 3)
Hodgkin Disease (Phase 4)
Leukemia (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Rectal Neoplasms (Phase 3)
Sarcoma (Phase 2)
Stomach Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)